Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Digestive Diseases and Sciences

• Publication date

  2011-04-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s10620-010-1384-1PMID 20737210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mucosal flora in Crohn's disease and ulcerative colitis - an overview.

  2009cited by this paper
• Differential NF-κB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance

  2009cited by this paper
• Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate

  2008cited by this paper
• The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing

  2008cited by this paper
• Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa.

  2008influential reference
• Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function.

  2007cited by this paper
• The role of the intestinal microbiota in the development of atopic disorders

  2007cited by this paper
• Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice.

  2007cited by this paper
• Regulation of B-lymphocyte activation by the PH domain adaptor protein Bam32/DAPP1.

  2007cited by this paper
• Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.

  2007cited by this paper
• Aggregating Phenotype in Lactobacillus crispatus Determines Intestinal Colonization and TLR2 and TLR4 Modulation in Murine Colonic Mucosa

  2007influential reference
• Probiotic effects on inflammatory bowel disease.

  2007cited by this paper
• In vivo association to human colon of Lactobacillus paracasei B21060: map from biopsies.

  2006cited by this paper
• Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice.

  2006cited by this paper
• Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease

  2006cited by this paper
• Sodium Butyrate-Mediated Sp3 Acetylation Represses Human Insulin-Like Growth Factor Binding Protein-3 Expression in Intestinal Epithelial Cells

  2006cited by this paper
• Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study

  2006cited by this paper
• Commensal gut bacteria: mechanisms of immune modulation.

  2005influential reference
• BACTERIAL INTERACTIONS WITH CELLS OF THE INTESTINAL MUCOSA: TOLL-LIKE RECEPTORS AND NOD2

  2005cited by this paper
• Molecular Characterization of Rectal Mucosa‐Associated Bacterial Flora in Inflammatory Bowel Disease

  2005cited by this paper
• Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice.

  2005influential reference
• Intestinal epithelial TOLLerance versus inTOLLerance of commensals.

  2005cited by this paper
• Obesity alters gut microbial ecology.

  2005cited by this paper
• Probiotics in inflammatory bowel disease: possible mechanisms of action

  2005cited by this paper
• Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

  2004cited by this paper
• Inferences, questions and possibilities in Toll-like receptor signalling

  2004cited by this paper
• Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

  2004cited by this paper
• Toll-like receptors as an escape mechanism from the host defense.

  2004cited by this paper
• Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C.

  2004cited by this paper
• Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA

  2004cited by this paper
• Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease.

  2004cited by this paper
• High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease.

  2004cited by this paper
• Identification of microorganisms by PCR amplification and sequencing of a universal amplified ribosomal region present in both prokaryotes and eukaryotes.

  2004cited by this paper
• Characterization of Bacterial Communities in Feces from Healthy Elderly Volunteers and Hospitalized Elderly Patients by Using Real-Time PCR and Effects of Antibiotic Treatment on the Fecal Microbiota

  2004cited by this paper
• Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease

  2004cited by this paper
• Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

  2003cited by this paper
• Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

  2003cited by this paper
• The Suppressive Effect of Bifidobacteria on Bacteroides vulgatus, a Putative Pathogenic Microbe in Inflammatory Bowel Disease

  2003cited by this paper
• Strategic Compartmentalization of Toll-Like Receptor 4 in the Mouse Gut1

  2003cited by this paper
• The mechanisms of action of PPARs.

  2002cited by this paper
• The Bacterial Flora in Inflammatory Bowel Disease: Current Insights in Pathogenesis and the Influence of Antibiotics and Probiotics

  2001cited by this paper
• Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease

  2000cited by this paper
• Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial

  2000cited by this paper
• Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis

  1999cited by this paper
• Direct Analysis of Genes Encoding 16S rRNA from Complex Communities Reveals Many Novel Molecular Species within the Human Gut

  1999cited by this paper
• Enteric Microflora in IBD: Pathogens or Commensals?

  1997cited by this paper
• Enteric Microflora in IBD: Pathogens or Commensals?

  1997cited by this paper
• Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification.

  1995cited by this paper
• Histologic and colonoscopic assessment of disease extension in ulcerative colitis.

  1987cited by this paper
• Variation Between Observers in Describing Mucosal Appearances in Proctocolitis*

  1964cited by this paper
• The course and prognosis of ulcerative colitis

  1963cited by this paper
• The Treatment of Asthma with Corticotrophin

  1955cited by this paper
• Kinase-Mitogen-Activated Protein Kinase Signal-Regulated Modulation of Extracellular Distinct Th Responses via Differential Agonists Instruct Dendritic Cells to Induce Cutting Edge: Different Toll-Like Receptor

  year unknowncited by this paper

• Probiotics in the Management of Chronic Bacterial Prostatitis Patients: A Randomized, Double-Blind Trial to Evaluate a Possible Link Between Gut Microbiota Restoring and Symptom Relief

  2025cites this paper
• Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence

  2025cites this paper
• Recent developments in managing luminal microbial ecology in patients with inflammatory bowel disease: from evidence to microbiome-based diagnostic and personalized therapy

  2025cites this paper
• Application of zein nanoparticles for the treatment of inflammatory bowel diseases

  2025cites this paper
• Survival and Impact on Microbial Diversity of Lacticaseibacillus paracasei DG in a Simulation of Human Intestinal Microbial Ecosystem

  2025cites this paper
• Post-infectious irritable bowel syndrome: Focus on serotonin metabolism disturbances and gut microbiota modulation

  2025cites this paper
• Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management

  2025cites this paper
• Postulating the Role of Piccha basti in Modulation of Gut Microbes – A Narrative Review

  2025cites this paper
• Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials

  2024cites this paper
• Oral administration of Lactobacillus casei DG® after ileostomy closure in restorative proctocolectomy: a randomized placebo-controlled trial (microbiota and immune microenvironment in pouchitis -MEP1)

  2024cites this paper
• Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances.

  2024cites this paper
• Probiotics for inflammatory bowel disease: Is there sufficient evidence?

  2024cites this paper
• A probiotic bi-functional peptidoglycan hydrolase sheds NOD2 ligands to regulate gut homeostasis in female mice

  2023cites this paper
• Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

  2023cites this paper
• Comparative efficacy and tolerability of probiotic, prebiotic, and synbiotic formulations for adult patients with mild-moderate ulcerative colitis in an adjunctive therapy: A network meta-analysis.

  2023cites this paper
• Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration

  2023cites this paper
• Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022

  2023cites this paper
• The Role of Probiotics in Inducing and Maintaining Remission in Crohn’s Disease and Ulcerative Colitis: A Systematic Review of the Literature

  2023cites this paper
• Immunological consequences of microbiome-based therapeutics

  2023cites this paper
• Changes of intestinal microbiota and microbiota-based treatments in IBD

  2022cites this paper
• Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update

  2022cites this paper
• Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease

  2022cites this paper
• Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches

  2022cites this paper
• Probiotics in the Treatment of Inflammatory Bowel Disease in Adulthood: A Systematic Review.

  2022cites this paper
• Lactobacillus plantarum strains attenuated DSS-induced colitis in mice by modulating the gut microbiota and immune response

  2022cites this paper
• A recombinant Bifidobacterium bifidum BGN4 strain expressing the streptococcal superoxide dismutase gene ameliorates inflammatory bowel disease

  2022cites this paper
• Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study.

  2022cites this paper
• Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats.

  2022cites this paper
• Probiotics Modulate Mouse Gut Microbiota and Influence Intestinal Immune and Serotonergic Gene Expression in a Site-Specific Fashion

  2021cites this paper
• Toll-Like Receptors as Drug Targets in the Intestinal Epithelium.

  2021cites this paper
• Advancements in the Pharmaceutical Applications of Probiotics: Dosage Forms and Formulation Technology

  2021cites this paper
• Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice

  2021cites this paper
• The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant Enterobacterales

  2021cites this paper
• Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells

  2021cites this paper
• Inovatif Gastroentero-Dermatoloji Kapsamında Muhtelif Yöntem Geliştirme I: Lactobacillus plantarum ve Lactobacillus paracasei ile Probiyotik Eneması Atopik Dermatitli Köpeklerde Anti-Pruritik Etkinlik Sağlar Mı?

  2021cites this paper
• Disease managing capacities and mechanisms of host effects of lactic acid bacteria

  2020cites this paper
• Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease

  2020cites this paper
• The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009–2020

  2020cites this paper
• Review of the relationships among polysaccharides, gut microbiota, and human health.

  2020cites this paper
• Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

  2020cites this paper
• Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD): Where Are We Now And Where Are We Going?Funders.

  2020cites this paper
• PTPRO exaggerates inflammation in ulcerative colitis through TLR4/NF‐κB pathway

  2020cites this paper
• Therapeutic applications of probiotics in ulcerative colitis: An updated review

  2020cites this paper
• Use of Probiotics in Inflammatory Bowel Disease

  2019cites this paper
• First and second generation probiotic therapeutics for Inflammatory Bowel Disease

  2019cites this paper
• The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis

  2019cites this paper
• Prospects of Using Microbiota Correction Methods in the Treatment of Inflammatory Bowel Disease

  2019cites this paper
• Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

  2018cites this paper
• Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice.

  2018cites this paper
• Gut colonization with extended-spectrum &bgr;-lactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis

  2018cites this paper
• Quantitative Recovery of Viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) After Gastrointestinal Passage in Healthy Adults

  2018cites this paper
• A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice

  2018cites this paper
• Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population

  2018cites this paper
• A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases

  2018cites this paper
• Pancreatitis-associated protein (pap) produced by different lactic acid bacteria can protect mice in an acute colitis model after oral delivery.

  2018cites this paper
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Lactobacillus casei DG CNCM I-1572 and decreasing potentially pathogenic gastro-intestinal microorganisms (ID further assessment) pursuant to 13(1) of (EC) No 1924/200

  2018cites this paper
• Probióticos no tratamento e prevenção de recidivas das doenças inflamatórias intestinais: uma revisão

  2017cites this paper
• Clinical Evidence for the Microbiome in Inflammatory Diseases

  2017cites this paper
• The Use of Lactobacillus casei and Lactobacillus paracasei in Clinical Trials for the Improvement of Human Health

  2017cites this paper
• Role of intestinal microbiota and metabolites on gut homeostasis and human diseases

  2017cites this paper
• Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid

  2017cites this paper
• An Overview of Probiotic Research

  2017cites this paper
• Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572)

  2017cites this paper
• Probiotics and prebiotics in ulcerative colitis.

  2016cites this paper
• Therapeutic effects of triptolide via the inhibition of IL-1β expression in a mouse model of ulcerative colitis

  2016cites this paper
• Safety of synthetic l-ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97

  2016cites this paper
• A Novel Rhamnose-Rich Hetero-exopolysaccharide Isolated from Lactobacillus paracasei DG Activates THP-1 Human Monocytic Cells

  2016cites this paper
• The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.

  2016cites this paper
• Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin

  2015cites this paper
• The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials

  2015cites this paper
• Intracloacal inoculation, an effective screening method for determining the efficacy of probiotic bacterial isolates against Campylobacter colonization in broiler chickens.

  2015cites this paper
• The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration

  2015cites this paper
• The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.

  2015cites this paper
• Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults.

  2014cites this paper
• Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier.

  2014cites this paper
• The Efficacy of Probiotic Bacterial Isolates in Reducing Cecal Camylobacter Colonization in Broiler Chickens

  2014cites this paper
• Use of probiotics and prebiotics in inflammatory bowel

  2014cites this paper
• Nutrigenetics and Crohn’s Disease

  2013cites this paper
• The origins of pain in diverticular disease: peripheral or central?

  2013cites this paper
• The emerging therapy with probiotics in the management of inflammatory bowel disease: current status

  2013cites this paper
• Recombinant probiotic therapy in experimental colitis in mice.

  2012cites this paper
• Probiotics in the Management of Inflammatory Bowel Disease

  2012cites this paper
• Scientific opinion on the substantiation of health claims related to Lactobacillus casei DG CNCM I-1572 and decreasing potentially pathogenic gastro intestinal microorganisms (ID 2949, 3061, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.

  2012cites this paper
• Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis.

  2012cites this paper
• Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases.

  2012cites this paper
• The intestinal microbiota and chronic disorders of the gut

  2011cites this paper
• Importance of IL-10 Modulation by Probiotic Microorganisms in Gastrointestinal Inflammatory Diseases

  2011cites this paper
• The Role of Pre- and Probiotics in the Treatment of Inflammatory Bowel

  2011cites this paper
• Differential expression of TLR2, TLR4 and JNK in mucosa of ileal pouches for ulcerative colitis. Is there a role for bacterial antigen pathway in asymptomatic patients?

  2011cites this paper
• Cloning and characterization of a novel murine macrophage inflammatory protein-1 alpha receptor.

  1996cites this paper